NanoViricides (NYSE:NNVC) Research Coverage Started at StockNews.com

Analysts at StockNews.com started coverage on shares of NanoViricides (NYSE:NNVC) in a research report issued on Monday. The firm set a “sell” rating on the stock.

NanoViricides Stock Performance

Shares of NYSE NNVC opened at $1.18 on Monday. The stock has a market cap of $13.90 million, a PE ratio of -1.46 and a beta of 0.68. The business has a fifty day moving average of $1.22 and a two-hundred day moving average of $1.16. NanoViricides has a 52-week low of $1.00 and a 52-week high of $2.00.

NanoViricides (NYSE:NNVC) last issued its quarterly earnings data on Wednesday, February 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01.

Institutional Trading of NanoViricides

A number of hedge funds and other institutional investors have recently made changes to their positions in NNVC. Two Sigma Securities LLC acquired a new stake in shares of NanoViricides in the second quarter valued at $28,000. Northern Trust Corp increased its stake in shares of NanoViricides by 60.4% in the fourth quarter. Northern Trust Corp now owns 29,664 shares of the company’s stock valued at $30,000 after buying an additional 11,170 shares in the last quarter. UBS Group AG increased its stake in shares of NanoViricides by 114.5% in the first quarter. UBS Group AG now owns 17,448 shares of the company’s stock valued at $37,000 after buying an additional 9,314 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of NanoViricides in the third quarter valued at $59,000. Finally, Millennium Management LLC increased its stake in shares of NanoViricides by 59.1% in the fourth quarter. Millennium Management LLC now owns 67,346 shares of the company’s stock valued at $75,000 after buying an additional 25,012 shares in the last quarter. 10.30% of the stock is currently owned by institutional investors and hedge funds.

NanoViricides Company Profile

NanoViricides, Inc, a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases.